RT Journal Article
SR Electronic
T1 SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.24.21264081
DO 10.1101/2021.09.24.21264081
A1 Harold J. Manley
A1 Gideon N. Aweh
A1 Caroline M. Hsu
A1 Daniel E. Weiner
A1 Dana Miskulin
A1 Antonia M. Harford
A1 Doug Johnson
A1 Eduardo K. Lacson
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.09.24.21264081.abstract
AB Among patients receiving maintenance dialysis with a national US dialysis provider, fully vaccinated dialysis patients were significantly less likely to be diagnosed with COVID-19 or be hospitalized than unvaccinated patients. Ad26.COV2.S/Janssen vaccine had significantly worse outcomes, and mRNA-1273/Moderna the best. Among the 27 patients with breakthrough COVID-19 and anti-spike IgG antibodies measured, 23/27 (85%) breakthrough COVID-19 cases occurred at titers <2 U/L (lower limit of a positive response); 14 of these patients never developing Ab titers above 2 U/L. Only 3/27 were receiving immunosuppression. The potential use of antibody titers to guide vaccinations should be explored.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding was obtainedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective evaluation was reviewed and approved by WCG IRB (Work Order 1-1456342-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request